## 1 Estimating the effectiveness of shielding during pregnancy against SARS-CoV-2 in New

## 2 York City during the first year of the COVID-19 pandemic

- 3
- 4 Siyu Chen<sup>1\*</sup>, Elisabeth A Murphy<sup>2</sup>, Angeline G Pendergrass<sup>3</sup>, Ashley C Sukhu<sup>4</sup>, Dorothy
- 5 Eng<sup>4</sup>, Magdalena Jurkiewicz<sup>4</sup>, Iman Mohammed<sup>5</sup>, Sophie Rand<sup>2</sup>, Lisa J White<sup>1</sup>, Nathaniel
- 6 Hupert<sup>1,6,7</sup>, Yawei J Yang<sup>2,4</sup>\*
- 7

# 8 Affiliations:

- <sup>9</sup> <sup>1</sup> Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, Nuffield
- 10 Department of Medicine, University of Oxford, United Kingdom
- <sup>11</sup> <sup>2</sup> Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York,
- 12 NY, USA
- <sup>13</sup> <sup>3</sup> Department of Earth and Atmospheric Sciences, Cornell University, Ithaca, NY, USA
- 14 <sup>4</sup> New York Presbyterian-Weill Cornell Medicine, New York, NY USA
- <sup>5</sup> Department of Obstetrics and Gynecology, Weill Cornell Medicine, New York, NY, USA
- <sup>6</sup> Department of Population Health Sciences, Weill Cornell Medicine, New York, NY, USA
- <sup>17</sup> <sup>7</sup> Department of Medicine, Weill Cornell Medicine, New York, NY, USA
- 18
- 19 **\*Co-Corresponding Authors:**
- 20 Siyu Chen and Yawei J Yang
- 21 Department of Pathology & Laboratory Medicine
- 22 1300 York Ave, F-701
- 23 New York, NY 10065
- 24 <u>yang@med.cornell.edu</u> and <u>siyu.chen@ndm.ox.ac.uk</u>
- 25

#### 26 Abstract

27	Pregnant patients have increased morbidity and mortality in the setting of SARS-CoV-2
28	infection. The exposure of pregnant patients in New York City to SARS-CoV-2 is not well
29	understood due to early lack of access to testing and the presence of asymptomatic
30	COVID-19 infections. Before the availability of vaccinations, preventative (shielding)
31	measures, including but not limited to wearing a mask and quarantining at home to limit
32	contact, were recommended for pregnant patients. Using universal testing data from
33	2196 patients who gave birth from April through December 2020 from one institution in
34	New York City, and in comparison, with infection data of the general population in New
35	York City, we estimated the exposure and real-world effectiveness of shielding in
36	pregnant patients. Our Bayesian model shows that patients already pregnant at the
37	onset of the pandemic had a 50% decrease in exposure compared to those who became
38	pregnant after the onset of the pandemic and to the general population.
39	

# 40 Introduction

Pregnant patients make up a vulnerable patient population in any infectious disease outbreak. When New York City became the epicenter of COVID-19 pandemic in March 2020, the impact of SARS-CoV-2 infection on pregnant patients and their neonates was not well understood<sup>1</sup>. In addition, the prevalence of the disease in the pregnant population was difficult to capture given the lack of early testing and the presence of asymptomatic infected patients<sup>1,2</sup>.

47

During this period of uncertainty early in the pandemic, most national and regional public health authorities and medical care professionals advocated for the enforcement of protective measures including wearing masks, quarantining at home when possible, and keeping social distancing. These non-pharmaceutical interventions or shielding measures have been shown to be highly effective in mitigating epidemic curves in the larger population especially during different "lockdown" periods in myriad countries<sup>3-6</sup>

54 but the effectiveness among pregnant patients at that time are still unknown.

55

56 Studies have shown that pregnant patients are at higher risk of getting seriously ill from SARS-CoV-2 compared to non-pregnant patients<sup>7,8</sup>. A meta-analysis showed that 57 compared to non-pregnant patients of reproductive age with COVID-19, pregnant 58 patients are at increased risk of severe disease from COVID-19, with increased risk of ICU 59 admission mechanical ventilation, and death<sup>9,10</sup>. In this study we aim to model exposure 60 rates in the pregnant vs. general populations and evaluate the efficacy of both shielding 61 and behavior changes during pregnancy on reducing both infection exposure and its 62 ramifications for morbidity and mortality to SARS-CoV-2 among pregnant patients. The 63 64 estimation of effectiveness of shielding during pregnancy relies on the comparison of 65 estimates of past exposure to infection between pregnant patients and the general population. Serology tests can identify past infections and enable estimation of the 66 number of total infections. However, naturally formed immunoglobulins targeting the 67 virus (i.e., those generated by native infection and not vaccination) have been reported 68 to wane below the detectable level of serological assays quite rapidly (e.g., after several 69 months)<sup>11,12</sup>. The cumulative level of exposure to SARS-CoV-2 in a population therefore is 70 not directly measurable and has to be inferred through modeling. Here, we propose a 71 72 new method to estimate the cumulative exposure of SARS-CoV-2 among pregnant 73 patients and employ a peer-reviewed model to estimate the cumulative exposure among general population in New York City, accounting for expected levels of antibody 74 waning (seroreversion). These results have implications on future infectious disease 75 prevention strategies in pregnancy. 76

77

78 Results

#### 79 Dynamic model of SARS-CoV-2 infection

80 The time course of SARS-CoV-2 infection among pregnant patients can be reconstructed

81	utilizing both RT-PCR and serology testing results by following the timeline of a typical
82	SARS-CoV-2 infection. Most individuals, once infected, experience an incubation period
83	before developing some symptoms of COVID-19 infection, while some individuals will
84	remain asymptomatic throughout. The onset of RT-PCR positivity varies across
85	individuals and types of clinical specimens <sup>13</sup> but systematic review studies showed that
86	the highest percentage virus detection was from nasopharyngeal sampling between 0
87	and 4 days post-symptom onset at 89% (95% confidence interval (CI) 83% to 93%)
88	dropping to 54% (95% CI 47 to 61) after 10 to 14 days <sup>14</sup> . In addition to testing SARS-CoV-
89	2 RNA load using RT-PCR testing SARS-CoV-2-specific IgM and IgG antibody (in the
90	absence of vaccination) is another method for identifying history of infection. Although
91	the precise timing of IgM and IgG antibody detectability depends on the testing kits and
92	varies across different individuals <sup>15,16</sup> , on average the viral RNA is detectable one or two
93	weeks earlier by RT-PCR than the antibody detectable by serological assays <sup>16,17</sup> .
94	Assuming that the RT-PCR is positive before serology positivity, we divided the
95	population of pregnant patients into five compartments: 1) RT-PCR negative and
96	serology negative without previous exposure ( $X_{00}$ , naïve); 2) RT-PCR positive and
97	serology negative ( $X_{10}$ , early-phase infected); 3) RT-PCR positive and serology positive
98	( $X_{11}$ , middle-phase infected); 4) RT-PCR negative and serology positive ( $X_{01}$ , late-phase
99	infected), and 5) both RT-PCR and serology negative with history of previous infection
100	$(Z_{00}, \text{ past infected})$ (Table 1).
101	

1	0	1	

Variables	Definition
v	proportion of naïve population who are both RT-PCR and serology negative
X <sub>00</sub>	and never exposed
V	proportion of early-phase infected population who are RT-PCT positive but
X <sub>10</sub>	serology negative
X <sub>11</sub>	proportion of middle-phase infected population who are both RT-PCR and

	serology positive
v	proportion of late-phase infected population who are RT-PCR negative but
X <sub>01</sub>	serology positive
7	proportion of past infected population who are both RT-PCR and serology
Z <sub>00</sub>	negative but previously exposed

**102** *Table 1. A list of patient compartments or model variables and their definitions.* 

103

104 We next defined four transmission quantities or parameters to link these above


105 mentioned 5 time-based compartments: force of infection,  $\lambda_{\tau}$ ; average time lag

106 between virus detectability by the RT-PCR test and antibody detectability by the serology

assay,  $1/\tau$ ; average time lag between antibody detectability by the serology assay and

108 virus undetectability by the RT-PCR assay,  $1/\sigma$ ; and antibody decay rate,  $\beta$  (Figure 1).

109



110

111 Figure 1. Schematic diagram of the dynamic model structure for RT-PCR and serology status.

112 The whole length of infectious period for pregnant patients can be therefore

approximated by the sum of time delay between virus detectability and antibody

detectability and the average time lag between antibody detectability and virus

115 undetectability. We developed a dynamic model to study temporal changes of both RT-

116 PCR and serology status in pregnant patients (Figure 1) with associated variables (Table

1) and parameters. Further details about the model can be found in the Methodology

118 Section.

119

## 120 Longitudinal Cross-Sectional RT-PCR and Serology Results

121 We modeled the exposure of 2196 pregnant patients who delivered at a New York City

hospital from April 20, 2020 through December 27, 2020 based on SARS-CoV-2 testing 122 performed on discarded samples obtained from birth admission using data from 123 124 quantitative real-time polymerase chain reaction (RT-PCR) testing for SARS-CoV-2 viral 125 infection, or serology studies assaying levels of Immunoglobulin (Ig)G and IgM as a marker of the immune response to SARS-CoV-2 infection (Demographics in Table S1, 126 Materials and Methods). Of the 2196 patients, 2.7% were positive and 97.3% were 127 128 negative for RT-PCR testing results; and 11.2% were positive and 88.8% were negative and for serology testing results. For both tests combined, 2.2% were both positive for RT-129 PCR and serology, 0.5% were RT-PCR positive and serology negative, 9.0% were RT-PCR 130 negative and serology positive, and 88.3% were both RT-PCR negative and serology 131 132 negative.

133

### 134 Fitting data from pregnant patients to the dynamic model

The test results of RT-PCR and serology allow us to divide our population of pregnant 135 patients into four data-driven categories: a) both RT-PCR negative and serology negative; 136 b) RT-PCR positive and serology negative; c) both RT-PCR positive and serology positive; 137 and d) RT-PCR negative and serology positive. The challenge in getting from test results 138 to dynamic model compartments is that the first compartment ( $X_{00}$ , naïve) and the last 139 140 compartment ( $Z_{00}$ , past infected) in the dynamic model (Figure 1) both manifest as both 141 RT-PCR and serology negative, and are thus indistinguishable. To overcome this 142 challenge, we developed a Bayesian measurement model to fit the test result data, 143 which connects model predictions of the five time-based modeling-compartments to the measurements of the four data-driven categories. 144


145

Different models (1-4) were used to analyze different assumptions about the force

147 infection among pregnant patients. In model 1, we assumed the force of infection is

148 constant over time, and then relaxed the assumptions by assuming a time-varying force

- of infection in models 2-4 (for details of how these models differ, see the parameters in
- 150 Table 2). Model fitting results showed that predictions from all four dynamic models
- 151 have good agreement with measurements from the data-driven categories each
- 152 calendar week (Figure 2).



154 Figure 2. Time evolution measurements and fitted test-result model estimates of the SARS-CoV-2 RT-PCR and antibody 155 status among patients who gave birth between 20 April 2020 and 21 December 2020. Panel (A)-(D) respectively shows 156 the model fitting results for four data-driven categories: A) both RT-PCR negative and serology negative; B) RT-PCR 157 positive and serology negative; C) both RT-PCR positive and serology positive; and D) RT-PCR negative and serology 158 positive. In each panel, the orange solid circles and black error bars represent the measured proportion of patients 159 who were giving birth and in one of the four RT-PCR and serology categories and their credible intervals respectively. 160 The green, orange, purple and pink lines in each panel show the median of estimates from Model 1-4, for proportions 161 of patients who were giving birth in each of the four categories, while the shaded areas correspond to the 90% credible 162 intervals. The models differ in the time-dependence of the force of infection; Model 1 assumes a constant force of 163 infection while Models 2-4 assume time-varying force of infection.

164

153

# 166 Transmission parameters of COVID-19 in pregnant patients are estimated to be

## 167 consistent with those estimated for general population

168 Data fitting allowed for the estimation of the transmission parameters. The posterior

- 169 estimates of parameters for pregnant patients from the four models were summarized in
- 170 Table 2Error! Reference source not found. The model also estimated the proportion of
- patients who were giving birth but not exposed to SARS-CoV-2  $(y_{00})$  by the beginning of
- 172 our study in April 2020.
- 173

Parameter(unit)	Definition	Model	Median	5%	95%
	average time lag	1	7	4	18
$\tau^{-1}(dovc)$	between virus	2	5	3	16
$ au^{-1}$ (days)	detectability and	3	5	3	10
	antibody detectability	4	6	4	13
	average time lag	1	22	14	37
$\sigma^{-1}$ (days)	between antibody	2	18	11	32
0 (uays)	detectability and virus	3	17	11	27
	undetectability	4	18	12	28
	average time lag	1	152	84	336
	between	2	118	64	270
$eta^{-1}$ (days)	seroconversion and	3	110	65	208
	seroreversion among pregnant patients	4	117	66	240
	proportion of patients	1	0.87	0.79	0.90
	who were giving birth	2	0.86	0.76	0.90
y <sub>00</sub> (-)	and not exposed by	3	0.86	0.74	0.89
	20 April 2020	4	0.85	0.74	0.89
$\lambda_{\tau}$ $\lambda_{11}(-)$	force of infection	1	0.0052	0.0022	0.010

λ <sub>21</sub> (-)		2	0.0063	0.0028	0.013
λ <sub>22</sub> (-)		Z	0.0079	0.0025	0.0182
λ <sub>31</sub> (-)			0.0041	0.0052	0.019
λ <sub>32</sub> (-)		3	0.011	0.0052	0.019
λ <sub>33</sub> (-)			0.0077	0.0030	0.019
λ <sub>41</sub> (-)			0.00013	0.000088	0.00072
λ <sub>42</sub> (-)		4	0.0095	0.0051	0.016
λ <sub>43</sub> (-)		4	0.0070	0.0013	0.0178
λ <sub>44</sub> (-)			0.0083	0.0033	0.019

174 Table 2. Parameter estimates (associated 90% credible intervals) among pregnant patients for each model fit.


We found that the estimates of the time difference between RT-PCR positivity and 175 176 serology positivity, and the duration of the infectious period for pregnant patients are very robust, on average 5.5 days (95% Credible Interval, Crl (3.3, 16.7) days), and 18.8 177 days (95% CrI (11.3, 34.3) days), respectively. These estimates are largely comparable 178 with those for the general population<sup>13,18-22</sup>. After seroconverting, seropositivity is 179 180 estimated to be maintained for 124 days on average (95% CrI: (63, 320) days) among exposed pregnant patients. This relatively rapid seroreversion is consistent with 181 estimates from the corresponding observational study, where analysis of the 182 183 relationship between the elapsed time from the date of symptom onset and the 184 antibody levels for pregnant patients demonstrated that the IgG positivity status could last approximately 110 days on average with a lower bound of the 95% confidence 185 interval of 82 days but with an upper bound that is uncertain and possibly very large<sup>2</sup>. 186 187 Estimated SARS-CoV-2 exposure in pregnant patients is higher than seropositivity rates 188 would suggest 189 The estimated seroprevalence (proportion of pregnant patients who are seropositive) 190

191 from each of the dynamic models (Figure 3) match that of our data (Figure 2B-D). We

next estimated the exposure to SARS-CoV-2 in the pregnant patients and found that exposure is estimated to be much higher than serology positivity (Figure 3). Due to the rapid decline in antibody levels after natural infection confirmed in both experimental analyses<sup>23-25</sup> and modelling analyses<sup>11,12</sup>, there is a gap between seropositivity and the cumulative level of exposure; furthermore, this gap increases with time due to increasing exposure levels over time (Figure 3).



199



200 Figure 3. Time evolution of SARS-CoV-2 exposure and seroprevalence among patients who gave birth

201 between 20 April 2020 and 21 December 2020. The orange solid circles and black error bars represent the

202 measured proportion of patients who were giving birth and serology positive and their credible intervals

- 203 respectively. The green, orange, purple and pink lines show the median estimates of exposure for patients
- 204 who were giving birth from Model 1, Model 2, Model 3 and Model 4 respectively; shaded areas correspond

205 to 90% credible intervals. The light green, yellow, brown and grey lines show the median estimates of

seroprevalence for patients who were giving birth from Model 1, Model 2, Model 3 and Model 4

207 respectively; shaded areas correspond to 50% credible intervals.

# 208 SARS-CoV-2 exposure in pregnant patients at the time of birth rose from half that of 209 the general population to equal that of the general population by late 2020

- 210 We next compared cumulative level of exposure among pregnant patients with of the
- 211 general population of New York City from the same time period. In brief, the levels of
- 212 exposure in general population were estimated by applying our previously published
- inference methodology<sup>11</sup> to the epidemic data including mortality and seroprevalence in
- 214 general population of New York City (model fitting and parameter estimation results for
- the general population can be found in Figure S1 and Error! Reference source not
- 216 found. Table S respectively). The level of exposure in pregnant patients during April and
- 217 May of 2020 is estimated to be around half of that in December 2020 in all four models
- 218 (Figure 3 and 4). This means that the exposure estimates of pregnant patients
- approaches that of the general population by November and December of 2020 (Figure
- 220 4).
- 221




Figure 4. Comparisons of estimates of exposure in patients who were giving birth from four models and general population. The red line shows the median estimates of exposure from general population while the shaded areas correspond to the 95% credible interval; the green, yellow, green, blue and pink line shows the median estimates of exposure from Model 1, Model 2, Model 3 and Model 4 for patients who were giving birth respectively, while the deep and shadow shaded areas correspond to the 50% credible intervals.

229

#### 230 Discussion

Positive results from RT-PCR testing and serology testing can both be used to identify 231 infected or recently infected individuals. While an infected individual turns RT-PCR 232 positive and then RT-PCR negative within the span of days to a week, a positive serology 233 234 test result can serve as a maintained marker of infection that last for months. By capturing this dynamic effect of antibody waning in our models, we found that SARS-235 CoV-2 exposure estimates were much higher than the seroprevalence estimates for our 236 237 sample of pregnant patients and the general public in New York City. These results confirm that previous studies looking at RT-PCR positive testing rates or seroprevalence 238 alone will substantially underestimate population-level and subgroup exposure to SARS-239 CoV-2. 240

241

We found that patients who gave birth between April and August of 2020 had lower 242 levels of exposure to SARS-CoV-2 compared to the general population. In fact, in the first 243 244 months of the pandemic (April and May 2020), the exposure levels of pregnant patients 245 were half of the exposure levels of the general population in New York City, and half of the exposure levels in pregnant patients who gave birth by the end of 2020. To 246 247 understand the possible variables that contribute to this lower exposure level in pregnant patients who gave birth early in 2020, we must take into account the 248 distinctions between the experience of pregnant patients who gave birth in early 2020 249 vs. late 2020. Patients that gave birth before August 2020—before the level of exposure 250 in pregnant patients became comparable to that of non-pregnant patients—were all at 251

252 least in their mid to late first trimester by the time that the pandemic hit New York City. This means that most of these patients had a high probability of knowing about their 253 254 pregnancy at the onset of the pandemic, and it is possible that this knowledge of 255 pregnancy led to behavior changes that made them more cautious than the general population. In contrast, the patients giving birth towards the end of 2020 were not 256 pregnant and/or did not know of their pregnancy before the onset of the pandemic and 257 258 may not have behaved differently than the general population; in other words, they could be considered part of general population in early 2020. During the early part of 259 the pandemic, the population only had access to shielding measures and other non-260 pharmaceutical measures for prevention of disease exposures (since vaccinations only 261 262 became available for the general population in early 2021). Thus, the reduction exposure 263 in pregnant patients by about half early in the pandemic may be attributed to effectiveness of shielding measures (Table S5). Our current data do not address whether 264 pregnant patients (especially those that gave birth early in the pandemic) were more 265 stringent than the general population in following recommendations for behavioral 266 267 changes and other non-pharmaceutical interventions, or whether they had additional means of improving the efficacy of shielding in preventing exposure. It is less likely that 268 biologic differences from the state of being pregnant contributed to exposure 269 270 differences as the pregnant patients that gave birth later in 2020 had similar exposures 271 to the general population.

272

Such a high-level reduction of exposure might have been associated with a reduction in
infection and especially a reduction of severe COVID-19 illness and, consequently, in
mortality in pregnant patients. A large-scale retrospective analysis from a database that
covers about 20% of the American population and includes 406 446 patients hospitalized
for childbirth (6380 (1.6%) of whom had COVID-19) compared outcomes for pregnant
patients with and without COVID-19 from April–November 2020<sup>26</sup>. It concluded that in-

hospital maternal death was rare, but rates were significantly higher for patients with 279 COVID-19 (141/100 000 patients, 95% CI 65–268) than for patients without COVID-19 280 281 (5/100 000 patients, 95% Cl 3.1–7.7). The estimate of maternal death rate is consistent with the study from the UK AAP SONPM registry, where a perinatal maternal mortality 282 rate of 167/100 000 (for patients who have COVID-19 around the time of birth) was 283 estimated<sup>9,27</sup>. Further calculation shows that the 40% to 50% reduction on exposure to 284 SARS-CoV-2 estimated by our study might have led to the prevention of 70 (95% CI 26-285 134) per 100,000 maternal deaths in New York City. 286

287

After the period included in our study, additional SARS-CoV-2 preventative measures in 288 289 the form of vaccinations were introduced in 2021 although strict quarantine regulations 290 were also lifted from the city by then. Pregnant patients were not included in studies testing the safety and efficacy of COVID-19 vaccines. Studies conducted since the start of 291 vaccination distribution including those looking at the real-word implementation of 292 vaccination have confirmed the safety and effectiveness of vaccines specifically for 293 pregnant patients, their placentas, and their neonates<sup>28-32</sup>. In fact, one study showed 294 that vaccinated pregnant patients had almost 50:1 lower odds of severe COVID-19 295 infection<sup>32</sup>. Our data highlights the utility of shielding measures, and argues for an 296 297 integrated intervention as suggested by CDC and NHS guidelines, which includes a 298 combination of vaccination and shielding to reduce the morbidity and mortality of 299 COVID-19 during pregnancy.

300

Our study has several important strengths, the two most important of which are robust data on a cohort of pregnant patients assessed over an extended period of time tested with both RT-PCR and serology throughout 2020, and the use of a novel model for reproducibly calculating disease exposure from testing data. While the lacuna in data capture in May and June could potentially influence the performance of parameter

306	inference, varying model assumptions on the force of infection (as detailed in the
307	Materials and Methods) found the estimated parameters and level of exposure to be
308	robust and therefore clarified the likely minimal impact caused by missing data.
309	
310	While the pregnant patient population is from a single NYC institution which may not be
311	representative of the broader population, this population allowed for uniformity in
312	testing and the study of a large cohort of patients.
313	
314	Our model was structured to recapitulate the average course of SARS-CoV-2 infection
315	with turning RT-PCR positive occurring before becoming serology positive. However, not
316	all disease courses follow this linear model structure. It is also possible that the state of
317	pregnancy may alter the susceptibility to SARS-CoV-2 infection, although current
318	evidence does not support that pregnancy increases the susceptibility of infection. In
319	addition, the antibody decaying rate may differ during pregnancy. We should note that
320	the thresholds of seropositive and seronegative assignment might vary between assays,
321	and the performances of assays (including sensitivity and specificity) are different. Our
322	study is not set up for longitudinal follow-up of our cohort, thus our data is not sufficient
323	to evaluate the impact of pregnancy on the antibody decaying rate. While more detailed
324	longitudinal serological data could be collected and modelled during pregnancy,

incorporating antibody kinetics into transmission models may hinder the applicability of
 estimates resulting from different assays<sup>11</sup>.

327

In summary, we used a novel model to evaluate SARS-CoV-2 exposure levels in different populations using seroprevalence data and RT-PCR data, comparing exposure levels in pregnant patients in New York City to the levels in the general City population. This permits us to quantify the impact of shielding measures in preventing exposure during pregnancy across the first year of the pandemic. We estimate the impact of self-

- protection on reducing the level of exposure among pregnant patients during early 2020
- who gave birth in this New York City hospital to be approximately 50%. These results,
- showing time-varying differences in exposure to SARS-CoV-2 in pregnant compared to
- non-pregnant populations, may have led to significant reduction in maternal morbidity
- and mortality in the early months of the pandemic. The estimated total exposure in
- 338 pregnant patients and general population of New York City are both more than double
- the latest serology positive measurements.

340

#### 342 Materials and Methods

#### 343 **Pregnant patients data**

344 Pregnant patients giving birth at a single New York City hospital between 20 April 2020 345 and 27 December 2020 were included in this study (Table S1). 2682 pregnant patients with clinical data capture and sample capture could have had either RT-PCR testing or 346 serology testing or were untested (unknown). Among these 2682 patients in terms of 347 348 RT-PCR, 97.7% were tested and 2.3% were unknown; in terms of serology tests, 89.9% were tested and 10.1% were unknown. For testing results breakdown: 10% were RT-PCR 349 negative but serology unknown; 0.3% were both RT-PCR and serology unknown; 8.1% 350 were RT-PCR negative and serology positive, 0.075% were RT-PCR unknow and serology 351 352 positive, 2.1% were both RT-PCR and serology positive, 77.18% were both RT-PCR and 353 serology negative, 2.0% RT-PCR unknown and serology negative, and 0.56% were RT-PCR positive and serology negative. After screening the distribution of unknow tests 354 355 results for PCR and serology on the calendar week, 2196 pregnant patients were included in the mathematical modelling. 356 357

The serology was detected in the serum or plasma from peripheral blood collected 358 during admission for delivery. The serology test was performed using the clinical testing 359 Pylon 3D platform (ET HealthCare, Palo Alto, CA). The Pylon 3D platform<sup>32</sup> utilizes a 360 361 fluorescence-based reporting system that allows for the semiquantitative detection of antie-SARS-CoV-2 IgG and IgM with a specificity of 98.8% and 99.4%, respectively. In this 362 paper, we denoted the serology status of every pregnant patient as positive if either IgG 363 or IgM was positive and as negative if both IgG and IgM were negative. 364 365 Pregnant patients underwent RT-PCR testing for SARS-CoV-2 using nasopharyngeal

366 swabs.

367 The observed cross-sectional data for pregnant patients is restructured into four

368 trajectories for model fitting: weekly proportion of RT-PCR and serology negative time-

369 series, weekly proportion of RT-PCR positive and serology negative time-series, weekly

- 370 proportion of RT-PCR positive and serology positive time-series and weekly proportion
- 371 of RT-PCR negative and serology positive time-series.

### 372 General population data

- 373 The seroprevalence data for general population in New York City Metro Area (including
- 374 Manhattan, Bronx, Queens, Kings and Nassau) from February 2020 to December 2020
- and the daily total (including confirmed and probability) mortality data were extracted
- 376 from US Department of Health and Human Services Centers for Disease Control and
- 377 Prevention CDC Data Tracker<sup>33</sup>. Details of the seroprevalence data used here can be
- 378 found elsewhere<sup>12,34</sup>.
- 379

# 380 Exposure inference in pregnant patients

We first develop a dynamic model diagramed in Figure 1 for the temporary changing status of RT-PCR and serology among pregnant patients based on the COVID-19 disease progression. Transmission parameters specific to pregnant patients are defined in the dynamic model (Table 2). A set of ordinary differential equations (ODEs) describing the time evolution of  $X_{00}, X_{10}, X_{11}X_{01}$  and  $Z_{00}$  can be written as follows:

386

$$387 \quad \frac{dX_{00}(t)}{dt} = -\lambda_{\tau}(t)X_{00}$$

$$388 \quad \frac{dX_{10}(t)}{dt} = \lambda_{\tau}(t)X_{00} - \tau X_{10}$$

$$389 \quad \frac{dX_{11}(t)}{dt} = \tau X_{10} - \sigma X_{11}$$

$$390 \quad \frac{dX_{01}(t)}{dt} = \sigma X_{11} - \beta X_{01}$$

$$391 \quad \frac{dZ_{00}(t)}{dt} = \beta X_{01}$$

$$392$$

Equation 1

The initial conditions of  $X_{00}, X_{10}, X_{11}, X_{01}$  and  $Z_{00}$  at t = 0 are denoted as  $y_{00}, x_{10}, x_{11}, x_{01}$  and  $z_{00}$ . Here, t = 0 refers to 20 April 2020 (calendar week 17 in

2020) when the first data of pregnant patients was collected. The minimum time step in

the ODEs is one week. We reparametrize the initial conditions as follows

398 
$$x_{10} = k_{10}(1 - y_{00})$$
  
399  $x_{11} = k_{11}(1 - y_{00} - k_{10}(1 - y_{00}))$   
400  $x_{01} = k_{01}(1 - y_{00} - k_{10}(1 - y_{00}) - k_{11}(1 - y_{00} - k_{10}(1 - y_{00})))$   
401  $z_{00} = 1 - x_{10} - x_{11} - x_{01}$   
402 Equation 2

403 where  $\{k_{10}, k_{11}, k_{01}\}$  are tool parameters and constrained between 0 and 1 so that

404  $\{x_{01}, x_{11}, x_{10}, z_{00}\}$  can be constrained between 0 and 1. This is mainly for the

405 convenience of MCMC implementation in Rstan. The posterior estimates of

406  $\{k_{10}, k_{11}, k_{01}\}$  in each model can be found in Figure S4.

407 In Equation 1,  $\{\lambda_{\tau}(t)\}\$  is the force of infection. We first assume  $\lambda_{11}(t)$  is constant over 408 time ( $17 \le t \le 53$ ) in Model 1 and then relax it by assuming a piece-wise constant at a 409 fixed time step. To test the sensitivity, we try several different steps including 18 weeks 410 in Model 2,

 $\begin{cases} \lambda_{21}, & 17 \le t < 35 \\ \lambda_{22}, & 35 \le t \le 53 \end{cases}$ 

411

412

413 12 weeks in Model 3,

(*31)	$17 \le t < 29$
	$29 \le t < 41$
$(\lambda_{33},$	$41 \le t \le 53$
	$\{\lambda_{32},$

415

Equation 4

Equation 3

416 and 9 weeks in Model 4,

417  

$$\begin{cases}
\lambda_{41}, & 17 \le t < 26 \\
\lambda_{42}, & 26 \le t < 35 \\
\lambda_{43}, & 35 \le t < 44 \\
\lambda_{44}, & 44 \le t \le 53
\end{cases}$$

418 Equation 5  
419 and then compare main model results. We denote the numerical solutions of ODE  
420 system defined in Equation 1 as 
$$\hat{X}_{00}, \hat{X}_{10}, \hat{X}_{11}, \hat{X}_{01}$$
 and  $\hat{Z}_{00}$ .  
421  
422 Following the dynamic model, we develop a Bayesian measurement model to model the  
423 data observation process so that the parameter estimation and model fitting can be  
424 conducted simultaneously using MCMC in Rstan<sup>35</sup>. The model with associated  
425 parameters (Table S) is described as follows:  
426  
427  $\lambda_{ij} \sim uniform(0,1), \lambda_{ij} \in [0,1]$   
428  $\sigma \sim uniform(0,1), \sigma \in [0,1]$   
429  $\tau \sim gamma(4,3), \tau \in [0.5]$   
430  $\beta \sim uniform(0,1), \beta \in [0,1]$   
431  $y_{00} \sim beta(8,2), y_{00} \in [0,1]$   
432 Equation 6  
433  $\left(x_{00}^{obs}(t), x_{10}^{obs}(t), x_{01}^{obs}(t)\right)$   
434  $\sim Multinomial(N(t), \hat{X}_{00}(t) + \hat{Z}_{00}(t), \hat{X}_{10}(t), \hat{X}_{11}(t), \hat{X}_{01}(t))$   
435 Equation 7  
436 where  $x_{00}^{obs}(t), x_{10}^{obs}(t), x_{10}^{obs}(t)$  are the measured numbers of pregnant

where  $x_{00}(t), x_{10}(t), x_{11}(t)$  and  $x_{01}(t)$  are the measured numbers of pregnant patients at calendar week t who were a) both RT-PCR and serology negative, b) RT-PCR positive and serology negative, c) both RT-PCR and serology positive and d) RT-PCR negative and serology positive respectively.  $\hat{X}_{10}(t), \hat{X}_{11}(t), \hat{X}_{01}(t)$  are ODE-predicted individuals at calendar week t who were in RT-PCT positive and serology negative, RT-PCT positive and serology positive, RT-PCT negative and serology positive respectively.  $\hat{X}_{00}(t) + \hat{Z}_{00}(t)$  is the ODE-predicted total number of pregnant patients at calendar

443 week t who were either both RT-PCT and serology negative.

444

445	We use Bayesian inference (Hamiltonian Monte Carlo algorithm) in RStan to fit the
446	model to RT-PCR and serology data by running four chains of 20,000 iterations each
447	(burn-in of 10,000). We use 5% and 95% percentiles from the resulting posterior
448	distributions for 90% CrI for the parameters. The Gelman–Rubin diagnostics ( $\widehat{R}$ ) given in
449	Table S show values of 1, indicating that there is no evidence of non-convergence for
450	either model formulation. Furthermore, the effective sample sizes ( $n_{eff}$ ) in Table S are
451	all more than 5,000, meaning that there are many samples in the posterior that can be
452	considered independent draws.
453	

### 454 **Exposure inference in general population**

For general population in New York City, we collected morality and seroprevalence time-455 series data as described in the Data Description section and fitted a published model 456 under the assumption of constant infection fatality ratio<sup>11</sup>. In the meanwhile, we got the 457 estimates of cumulative exposure over time and two parameters related to the general 458 population of New York City: they are infection fatality ratio,  $\alpha$  and antibody decaying 459 ratio,  $\omega$  (Table S). Through comparing the exposure level to SARS-CoV-2 among 460 461 pregnant patients and general population, we estimated the effectiveness of shielding 462 during pregnancy.

463

Acknowledgments: Y.J.Y. acknowledges funding from The Bender Foundation, Inc. and
Weill Cornell Medical Center. L.J.W. received financial support from the Li Ka Shing
Foundation and the University of Oxford's COVID-19 Research Response Fund. The
funders had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.

469

470 **Ethical issues:** IRB approval was obtained from Weill Cornell Medicine for this study.

471

# 472 **Author contributions:**

- 473 L.J.W., N.H., Y.J.Y. conceived and designed the study. E.A.M, Y.J.Y, A.C.S, D.E, S.R, I.M
- 474 provided patient samples and clinical information, or performed sample testing. S.C.,
- 475 E.A.M and Y.J.Y. cleaned the data, S.C., A.G.P. and L.J.W. developed the methodology and
- 476 conducted the formal analysis. S.C., Y.J.Y., E.A.M. and L.J.W. wrote the original
- 477 manuscript. All authors reviewed and provided analytical input and approved the
- 478 manuscript. Y.J.Y. and L.J.W. supervised the study.
- 479
- 480 **Competing interests:** The authors have declared that no competing interests exist.

481

- 482 Data and materials availability: All codes and materials used in the analyses can be
- 483 accessed at: <u>https://github.com/SiyuChenOxf/COVID-19Exposure-</u>
- 484 <u>ShieldingPregnantWomen</u>. All parameter estimates and figures presented can be
- reproduced using the code provided. This work is licensed under a Creative Commons
- 486 Attribution 4.0 International (CC BY 4.0) license, which permits unrestricted use,
- distribution, and reproduction in any medium, provided the original work is properly
- 488 cited. The datasets from pregnant patients can be made available from the
- 489 corresponding authors on reasonable request.
- 490

# 491 References

- Prabhu, M., et al. Pregnancy and postpartum outcomes in a universally tested
   population for SARS-CoV-2 in New York City: a prospective cohort study. BJOG: An
   International Journal of Obstetrics & Gynaecology 127, 1548-1556 (2020).
- Kubiak, J.M., *et al.* Severe acute respiratory syndrome coronavirus 2 serology levels
  in pregnant women and their neonates. *American journal of obstetrics and gynecology* 225, 73. e71-73. e77 (2021).
- Baker, R.E., *et al.* The impact of COVID-19 nonpharmaceutical interventions on the
  future dynamics of endemic infections. *Proceedings of the National Academy of Sciences* 117, 30547-30553 (2020).
- 4. Singh, S., Shaikh, M., Hauck, K. & Miraldo, M. Impacts of introducing and lifting

<ul> <li>nonpharmaceutical interventions on COVID-19 daily growth rate and compliance</li> <li>in the United States. <i>Proceedings of the National Academy of Sciences</i> 118(2021).</li> <li>Brauner, J.M., <i>et al.</i> Inferring the effectiveness of government interventions</li> <li>against COVID-19. <i>Science</i> 371, eabd9338 (2021).</li> <li>Flaxman, S., <i>et al.</i> Estimating the effects of non-pharmaceutical interventions on</li> <li>COVID-19 in Europe. <i>Nature</i> 584, 257-261 (2020).</li> <li>CDC: COVID-19 in Pregnant and Recently Pregnant People.</li> <li>NHS: Pregnancy and coronavirus (COVID-19).</li> <li>Ortiz, E.I., Herrera, E. &amp; De La Torre, A. Coronavirus (COVID 19) infection in</li> <li>pregnancy. <i>Colombia Médica</i> 51(2020).</li> <li>Qiao, J. What are the risks of COVID-19 infection in pregnant women? <i>The Lancet</i> 395, 760-762 (2020).</li> <li>Chen, S., Flegg, J.A., White, L.J. &amp; Aguas, R. Levels of SARS-CoV-2 population</li> <li>exposure are considerably higher than suggested by seroprevalence surveys. <i>PLoS computational biology</i> 17, e1009436 (2021).</li> <li>Shioda, K., <i>et al.</i> Estimating the cumulative incidence of SARS-CoV-2 infection and the infection fatality ratio in light of waning antibodies. <i>Epidemiology (Cambridge, Mass.</i>) 32, 518 (2021).</li> <li>Wang, W., <i>et al.</i> Detection of SARS-CoV-2 in different types of clinical specimens. <i>Jama</i> 323, 1843-1844 (2020).</li> <li>Mallett, S., <i>et al.</i> At what times during infection is SARS-CoV-2 detectable and no longer detectable using RT-PCR-based tests? A systematic review of individual participant data. <i>BMC medicine</i> 18, 1-17 (2020).</li> <li>Li, K., <i>et al.</i> Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-COV-2 infection in the general population. <i>Nature communications</i> 12, 1-11 (2020).</li> </ul>
<ol> <li>Brauner, J.M., et al. Inferring the effectiveness of government interventions against COVID-19. Science 371, eabd9338 (2021).</li> <li>Flaxman, S., et al. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe. Nature 584, 257-261 (2020).</li> <li>CDC: COVID-19 in Pregnant and Recently Pregnant People.</li> <li>NHS: Pregnancy and coronavirus (COVID-19).</li> <li>Ortiz, E.I., Herrera, E. &amp; De La Torre, A. Coronavirus (COVID 19) infection in pregnancy. Colombia Médica 51(2020).</li> <li>Qiao, J. What are the risks of COVID-19 infection in pregnant women? The Lancet 395, 760-762 (2020).</li> <li>Chen, S., Flegg, J.A., White, L.J. &amp; Aguas, R. Levels of SARS-CoV-2 population exposure are considerably higher than suggested by seroprevalence surveys. PLoS computational biology 17, e1009436 (2021).</li> <li>Shioda, K., et al. Estimating the cumulative incidence of SARS-CoV-2 infection and the infection fatality ratio in light of waning antibodies. Epidemiology (Cambridge, Mass.) 32, 518 (2021).</li> <li>Wang, W., et al. Detection of SARS-CoV-2 in different types of clinical specimens. Jama 323, 1843-1844 (2020).</li> <li>Mallett, S., et al. At what times during infection is SARS-CoV-2 detectable and no longer detectable using RT-PCR-based tests? A systematic review of individual participant data. BMC medicine 18, 1-17 (2020).</li> <li>Li, K., et al. Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19. Nature communications 11, 1-11 (2020).</li> <li>Wei, J., et al. Anti-spike antibody response to natural SARS-CoV-2 infection in the</li> </ol>
<ul> <li>against COVID-19. Science 371, eabd9338 (2021).</li> <li>Flaxman, S., et al. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe. Nature 584, 257-261 (2020).</li> <li>CDC: COVID-19 in Pregnant and Recently Pregnant People.</li> <li>NHS: Pregnancy and coronavirus (COVID-19).</li> <li>Ortiz, E.I., Herrera, E. &amp; De La Torre, A. Coronavirus (COVID 19) infection in pregnancy. Colombia Médica 51(2020).</li> <li>Qiao, J. What are the risks of COVID-19 infection in pregnant women? The Lancet 395, 760-762 (2020).</li> <li>Chen, S., Flegg, J.A., White, L.J. &amp; Aguas, R. Levels of SARS-CoV-2 population exposure are considerably higher than suggested by seroprevalence surveys. PLoS computational biology 17, e1009436 (2021).</li> <li>Shioda, K., et al. Estimating the cumulative incidence of SARS-CoV-2 infection and the infection fatality ratio in light of waning antibodies. Epidemiology (Cambridge, Mass.) 32, 518 (2021).</li> <li>Wang, W., et al. Detection of SARS-CoV-2 in different types of clinical specimens. Jama 323, 1843-1844 (2020).</li> <li>Mallett, S., et al. At what times during infection is SARS-CoV-2 detectable and no longer detectable using RT-PCR-based tests? A systematic review of individual participant data. BMC medicine 18, 1-17 (2020).</li> <li>Li, K., et al. Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19. Nature communications 11, 1-11 (2020).</li> <li>Wei, J., et al. Anti-spike antibody response to natural SARS-CoV-2 infection in the</li> </ul>
<ol> <li>Flaxman, S., et al. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe. Nature 584, 257-261 (2020).</li> <li>CDC: COVID-19 in Pregnant and Recently Pregnant People.</li> <li>NHS: Pregnancy and coronavirus (COVID-19).</li> <li>Ortiz, E.I., Herrera, E. &amp; De La Torre, A. Coronavirus (COVID 19) infection in pregnancy. Colombia Médica 51(2020).</li> <li>Qiao, J. What are the risks of COVID-19 infection in pregnant women? The Lancet 395, 760-762 (2020).</li> <li>Chen, S., Flegg, J.A., White, L.J. &amp; Aguas, R. Levels of SARS-CoV-2 population exposure are considerably higher than suggested by seroprevalence surveys. PLoS computational biology 17, e1009436 (2021).</li> <li>Shioda, K., et al. Estimating the cumulative incidence of SARS-CoV-2 infection and the infection fatality ratio in light of waning antibodies. Epidemiology (Cambridge, Mass.) 32, 518 (2021).</li> <li>Wang, W., et al. Detection of SARS-CoV-2 in different types of clinical specimens. Jama 323, 1843-1844 (2020).</li> <li>Mallett, S., et al. At what times during infection is SARS-CoV-2 detectable and no longer detectable using RT-PCR-based tests? A systematic review of individual participant data. BMC medicine 18, 1-17 (2020).</li> <li>Li, K., et al. Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19. Nature communications 11, 1-11 (2020).</li> <li>Wei, J., et al. Anti-spike antibody response to natural SARS-CoV-2 infection in the</li> </ol>
<ul> <li>COVID-19 in Europe. Nature 584, 257-261 (2020).</li> <li>CDC: COVID-19 in Pregnant and Recently Pregnant People.</li> <li>NHS: Pregnancy and coronavirus (COVID-19).</li> <li>Ortiz, E.I., Herrera, E. &amp; De La Torre, A. Coronavirus (COVID 19) infection in pregnancy. Colombia Médica 51(2020).</li> <li>Qiao, J. What are the risks of COVID-19 infection in pregnant women? The Lancet 395, 760-762 (2020).</li> <li>Chen, S., Flegg, J.A., White, L.J. &amp; Aguas, R. Levels of SARS-CoV-2 population exposure are considerably higher than suggested by seroprevalence surveys. PLoS computational biology 17, e1009436 (2021).</li> <li>Shioda, K., et al. Estimating the cumulative incidence of SARS-CoV-2 infection and the infection fatality ratio in light of waning antibodies. Epidemiology (Cambridge, Mass.) 32, 518 (2021).</li> <li>Wang, W., et al. Detection of SARS-CoV-2 in different types of clinical specimens. Jama 323, 1843-1844 (2020).</li> <li>Mallett, S., et al. At what times during infection is SARS-CoV-2 detectable and no longer detectable using RT-PCR-based tests? A systematic review of individual participant data. BMC medicine 18, 1-17 (2020).</li> <li>Li, K., et al. Anti-spike antibody response to natural SARS-CoV-2 infection in the</li> </ul>
<ol> <li>CDC: COVID-19 in Pregnant and Recently Pregnant People.</li> <li>NHS: Pregnancy and coronavirus (COVID-19).</li> <li>Ortiz, E.I., Herrera, E. &amp; De La Torre, A. Coronavirus (COVID 19) infection in pregnancy. <i>Colombia Médica</i> 51(2020).</li> <li>Qiao, J. What are the risks of COVID-19 infection in pregnant women? <i>The Lancet</i> 395, 760-762 (2020).</li> <li>Chen, S., Flegg, J.A., White, L.J. &amp; Aguas, R. Levels of SARS-CoV-2 population exposure are considerably higher than suggested by seroprevalence surveys. <i>PLoS</i> <i>computational biology</i> 17, e1009436 (2021).</li> <li>Shioda, K., <i>et al.</i> Estimating the cumulative incidence of SARS-CoV-2 infection and the infection fatality ratio in light of waning antibodies. <i>Epidemiology (Cambridge,</i> <i>Mass.)</i> 32, 518 (2021).</li> <li>Wang, W., <i>et al.</i> Detection of SARS-CoV-2 in different types of clinical specimens. <i>Jama</i> 323, 1843-1844 (2020).</li> <li>Mallett, S., <i>et al.</i> At what times during infection is SARS-CoV-2 detectable and no longer detectable using RT-PCR-based tests? A systematic review of individual participant data. <i>BMC medicine</i> 18, 1-17 (2020).</li> <li>Li, K., <i>et al.</i> Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19. <i>Nature communications</i> 11, 1-11 (2020).</li> <li>Wei, J., <i>et al.</i> Anti-spike antibody response to natural SARS-CoV-2 infection in the</li> </ol>
<ol> <li>8. NHS: Pregnancy and coronavirus (COVID-19).</li> <li>9. Ortiz, E.I., Herrera, E. &amp; De La Torre, A. Coronavirus (COVID 19) infection in pregnancy. <i>Colombia Médica</i> 51(2020).</li> <li>10. Qiao, J. What are the risks of COVID-19 infection in pregnant women? <i>The Lancet</i> 395, 760-762 (2020).</li> <li>11. Chen, S., Flegg, J.A., White, L.J. &amp; Aguas, R. Levels of SARS-CoV-2 population exposure are considerably higher than suggested by seroprevalence surveys. <i>PLoS</i> <i>computational biology</i> 17, e1009436 (2021).</li> <li>12. Shioda, K., <i>et al.</i> Estimating the cumulative incidence of SARS-CoV-2 infection and the infection fatality ratio in light of waning antibodies. <i>Epidemiology (Cambridge,</i> <i>Mass.)</i> 32, 518 (2021).</li> <li>13. Wang, W., <i>et al.</i> Detection of SARS-CoV-2 in different types of clinical specimens. <i>Jama</i> 323, 1843-1844 (2020).</li> <li>14. Mallett, S., <i>et al.</i> At what times during infection is SARS-CoV-2 detectable and no longer detectable using RT-PCR-based tests? A systematic review of individual participant data. <i>BMC medicine</i> 18, 1-17 (2020).</li> <li>15. Li, K., <i>et al.</i> Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19. <i>Nature communications</i> 11, 1-11 (2020).</li> <li>16. Wei, J., <i>et al.</i> Anti-spike antibody response to natural SARS-CoV-2 infection in the</li> </ol>
<ol> <li>Ortiz, E.I., Herrera, E. &amp; De La Torre, A. Coronavirus (COVID 19) infection in pregnancy. <i>Colombia Médica</i> 51(2020).</li> <li>Qiao, J. What are the risks of COVID-19 infection in pregnant women? <i>The Lancet</i> 395, 760-762 (2020).</li> <li>Chen, S., Flegg, J.A., White, L.J. &amp; Aguas, R. Levels of SARS-CoV-2 population exposure are considerably higher than suggested by seroprevalence surveys. <i>PLoS</i> <i>computational biology</i> 17, e1009436 (2021).</li> <li>Shioda, K., <i>et al.</i> Estimating the cumulative incidence of SARS-CoV-2 infection and the infection fatality ratio in light of waning antibodies. <i>Epidemiology (Cambridge,</i> <i>Mass.)</i> 32, 518 (2021).</li> <li>Wang, W., <i>et al.</i> Detection of SARS-CoV-2 in different types of clinical specimens. <i>Jama</i> 323, 1843-1844 (2020).</li> <li>Mallett, S., <i>et al.</i> At what times during infection is SARS-CoV-2 detectable and no longer detectable using RT-PCR-based tests? A systematic review of individual participant data. <i>BMC medicine</i> 18, 1-17 (2020).</li> <li>Li, K., <i>et al.</i> Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19. <i>Nature communications</i> 11, 1-11 (2020).</li> <li>Wei, J., <i>et al.</i> Anti-spike antibody response to natural SARS-CoV-2 infection in the</li> </ol>
<ul> <li>pregnancy. <i>Colombia Médica</i> 51(2020).</li> <li>10. Qiao, J. What are the risks of COVID-19 infection in pregnant women? <i>The Lancet</i> 395, 760-762 (2020).</li> <li>11. Chen, S., Flegg, J.A., White, L.J. &amp; Aguas, R. Levels of SARS-CoV-2 population exposure are considerably higher than suggested by seroprevalence surveys. <i>PLoS computational biology</i> 17, e1009436 (2021).</li> <li>12. Shioda, K., <i>et al.</i> Estimating the cumulative incidence of SARS-CoV-2 infection and the infection fatality ratio in light of waning antibodies. <i>Epidemiology (Cambridge, Mass.)</i> 32, 518 (2021).</li> <li>13. Wang, W., <i>et al.</i> Detection of SARS-CoV-2 in different types of clinical specimens. <i>Jama</i> 323, 1843-1844 (2020).</li> <li>14. Mallett, S., <i>et al.</i> At what times during infection is SARS-CoV-2 detectable and no longer detectable using RT-PCR-based tests? A systematic review of individual participant data. <i>BMC medicine</i> 18, 1-17 (2020).</li> <li>15. Li, K., <i>et al.</i> Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19. <i>Nature communications</i> 11, 1-11 (2020).</li> <li>16. Wei, J., <i>et al.</i> Anti-spike antibody response to natural SARS-CoV-2 infection in the</li> </ul>
<ol> <li>Qiao, J. What are the risks of COVID-19 infection in pregnant women? <i>The Lancet</i> 395, 760-762 (2020).</li> <li>Chen, S., Flegg, J.A., White, L.J. &amp; Aguas, R. Levels of SARS-CoV-2 population exposure are considerably higher than suggested by seroprevalence surveys. <i>PLoS</i> <i>computational biology</i> 17, e1009436 (2021).</li> <li>Shioda, K., <i>et al.</i> Estimating the cumulative incidence of SARS-CoV-2 infection and the infection fatality ratio in light of waning antibodies. <i>Epidemiology (Cambridge,</i> <i>Mass.)</i> 32, 518 (2021).</li> <li>Wang, W., <i>et al.</i> Detection of SARS-CoV-2 in different types of clinical specimens. <i>Jama</i> 323, 1843-1844 (2020).</li> <li>Mallett, S., <i>et al.</i> At what times during infection is SARS-CoV-2 detectable and no longer detectable using RT-PCR-based tests? A systematic review of individual participant data. <i>BMC medicine</i> 18, 1-17 (2020).</li> <li>Li, K., <i>et al.</i> Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19. <i>Nature communications</i> 11, 1-11 (2020).</li> <li>Wei, J., <i>et al.</i> Anti-spike antibody response to natural SARS-CoV-2 infection in the</li> </ol>
<ul> <li>395, 760-762 (2020).</li> <li>11. Chen, S., Flegg, J.A., White, L.J. &amp; Aguas, R. Levels of SARS-CoV-2 population exposure are considerably higher than suggested by seroprevalence surveys. <i>PLoS</i> <i>computational biology</i> 17, e1009436 (2021).</li> <li>12. Shioda, K., <i>et al.</i> Estimating the cumulative incidence of SARS-CoV-2 infection and the infection fatality ratio in light of waning antibodies. <i>Epidemiology (Cambridge,</i> <i>Mass.)</i> 32, 518 (2021).</li> <li>13. Wang, W., <i>et al.</i> Detection of SARS-CoV-2 in different types of clinical specimens. <i>Jama</i> 323, 1843-1844 (2020).</li> <li>14. Mallett, S., <i>et al.</i> At what times during infection is SARS-CoV-2 detectable and no longer detectable using RT-PCR-based tests? A systematic review of individual participant data. <i>BMC medicine</i> 18, 1-17 (2020).</li> <li>15. Li, K., <i>et al.</i> Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19. <i>Nature communications</i> 11, 1-11 (2020).</li> <li>16. Wei, J., <i>et al.</i> Anti-spike antibody response to natural SARS-CoV-2 infection in the</li> </ul>
<ol> <li>Chen, S., Flegg, J.A., White, L.J. &amp; Aguas, R. Levels of SARS-CoV-2 population exposure are considerably higher than suggested by seroprevalence surveys. <i>PLoS</i> <i>computational biology</i> 17, e1009436 (2021).</li> <li>Shioda, K., <i>et al.</i> Estimating the cumulative incidence of SARS-CoV-2 infection and the infection fatality ratio in light of waning antibodies. <i>Epidemiology (Cambridge,</i> <i>Mass.)</i> 32, 518 (2021).</li> <li>Wang, W., <i>et al.</i> Detection of SARS-CoV-2 in different types of clinical specimens. <i>Jama</i> 323, 1843-1844 (2020).</li> <li>Mallett, S., <i>et al.</i> At what times during infection is SARS-CoV-2 detectable and no longer detectable using RT-PCR-based tests? A systematic review of individual participant data. <i>BMC medicine</i> 18, 1-17 (2020).</li> <li>Li, K., <i>et al.</i> Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19. <i>Nature communications</i> 11, 1-11 (2020).</li> <li>Wei, J., <i>et al.</i> Anti-spike antibody response to natural SARS-CoV-2 infection in the</li> </ol>
<ul> <li>exposure are considerably higher than suggested by seroprevalence surveys. <i>PLoS</i></li> <li><i>computational biology</i> 17, e1009436 (2021).</li> <li>Shioda, K., <i>et al.</i> Estimating the cumulative incidence of SARS-CoV-2 infection and</li> <li>the infection fatality ratio in light of waning antibodies. <i>Epidemiology (Cambridge,</i></li> <li><i>Mass.</i>) 32, 518 (2021).</li> <li>Wang, W., <i>et al.</i> Detection of SARS-CoV-2 in different types of clinical specimens.</li> <li><i>Jama</i> 323, 1843-1844 (2020).</li> <li>Mallett, S., <i>et al.</i> At what times during infection is SARS-CoV-2 detectable and no</li> <li>longer detectable using RT-PCR-based tests? A systematic review of individual</li> <li>participant data. <i>BMC medicine</i> 18, 1-17 (2020).</li> <li>Li, K., <i>et al.</i> Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2</li> <li>infection and recovery from COVID-19. <i>Nature communications</i> 11, 1-11 (2020).</li> <li>Wei, J., <i>et al.</i> Anti-spike antibody response to natural SARS-COV-2 infection in the</li> </ul>
<ul> <li><i>computational biology</i> 17, e1009436 (2021).</li> <li>Shioda, K., <i>et al.</i> Estimating the cumulative incidence of SARS-CoV-2 infection and the infection fatality ratio in light of waning antibodies. <i>Epidemiology (Cambridge, Mass.)</i> 32, 518 (2021).</li> <li>Wang, W., <i>et al.</i> Detection of SARS-CoV-2 in different types of clinical specimens. <i>Jama</i> 323, 1843-1844 (2020).</li> <li>Mallett, S., <i>et al.</i> At what times during infection is SARS-CoV-2 detectable and no longer detectable using RT-PCR-based tests? A systematic review of individual participant data. <i>BMC medicine</i> 18, 1-17 (2020).</li> <li>Li, K., <i>et al.</i> Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19. <i>Nature communications</i> 11, 1-11 (2020).</li> <li>Wei, J., <i>et al.</i> Anti-spike antibody response to natural SARS-CoV-2 infection in the</li> </ul>
<ol> <li>Shioda, K., et al. Estimating the cumulative incidence of SARS-CoV-2 infection and the infection fatality ratio in light of waning antibodies. <i>Epidemiology (Cambridge,</i> <i>Mass.</i>) <b>32</b>, 518 (2021).</li> <li>Wang, W., et al. Detection of SARS-CoV-2 in different types of clinical specimens. <i>Jama</i> <b>323</b>, 1843-1844 (2020).</li> <li>Mallett, S., et al. At what times during infection is SARS-CoV-2 detectable and no longer detectable using RT-PCR-based tests? A systematic review of individual participant data. <i>BMC medicine</i> <b>18</b>, 1-17 (2020).</li> <li>Li, K., et al. Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19. <i>Nature communications</i> <b>11</b>, 1-11 (2020).</li> <li>Wei, J., et al. Anti-spike antibody response to natural SARS-CoV-2 infection in the</li> </ol>
<ul> <li>the infection fatality ratio in light of waning antibodies. <i>Epidemiology (Cambridge</i>, <i>Mass.</i>) <b>32</b>, 518 (2021).</li> <li>13. Wang, W., <i>et al.</i> Detection of SARS-CoV-2 in different types of clinical specimens. <i>Jama</i> <b>323</b>, 1843-1844 (2020).</li> <li>14. Mallett, S., <i>et al.</i> At what times during infection is SARS-CoV-2 detectable and no longer detectable using RT-PCR-based tests? A systematic review of individual participant data. <i>BMC medicine</i> <b>18</b>, 1-17 (2020).</li> <li>15. Li, K., <i>et al.</i> Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19. <i>Nature communications</i> <b>11</b>, 1-11 (2020).</li> <li>16. Wei, J., <i>et al.</i> Anti-spike antibody response to natural SARS-CoV-2 infection in the</li> </ul>
<ul> <li><i>Mass.</i>) 32, 518 (2021).</li> <li>13. Wang, W., et al. Detection of SARS-CoV-2 in different types of clinical specimens. <i>Jama</i> 323, 1843-1844 (2020).</li> <li>14. Mallett, S., et al. At what times during infection is SARS-CoV-2 detectable and no longer detectable using RT-PCR-based tests? A systematic review of individual participant data. <i>BMC medicine</i> 18, 1-17 (2020).</li> <li>15. Li, K., et al. Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19. <i>Nature communications</i> 11, 1-11 (2020).</li> <li>16. Wei, J., et al. Anti-spike antibody response to natural SARS-CoV-2 infection in the</li> </ul>
<ol> <li>Wang, W., et al. Detection of SARS-CoV-2 in different types of clinical specimens. Jama 323, 1843-1844 (2020).</li> <li>Mallett, S., et al. At what times during infection is SARS-CoV-2 detectable and no longer detectable using RT-PCR-based tests? A systematic review of individual participant data. BMC medicine 18, 1-17 (2020).</li> <li>Li, K., et al. Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19. Nature communications 11, 1-11 (2020).</li> <li>Wei, J., et al. Anti-spike antibody response to natural SARS-CoV-2 infection in the</li> </ol>
<ul> <li>Jama 323, 1843-1844 (2020).</li> <li>14. Mallett, S., et al. At what times during infection is SARS-CoV-2 detectable and no longer detectable using RT-PCR-based tests? A systematic review of individual participant data. BMC medicine 18, 1-17 (2020).</li> <li>15. Li, K., et al. Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19. Nature communications 11, 1-11 (2020).</li> <li>16. Wei, J., et al. Anti-spike antibody response to natural SARS-CoV-2 infection in the</li> </ul>
<ul> <li>Mallett, S., et al. At what times during infection is SARS-CoV-2 detectable and no longer detectable using RT-PCR-based tests? A systematic review of individual participant data. <i>BMC medicine</i> 18, 1-17 (2020).</li> <li>Li, K., et al. Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19. <i>Nature communications</i> 11, 1-11 (2020).</li> <li>Wei, J., et al. Anti-spike antibody response to natural SARS-CoV-2 infection in the</li> </ul>
<ul> <li>longer detectable using RT-PCR-based tests? A systematic review of individual participant data. <i>BMC medicine</i> 18, 1-17 (2020).</li> <li>Li, K., <i>et al.</i> Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19. <i>Nature communications</i> 11, 1-11 (2020).</li> <li>Wei, J., <i>et al.</i> Anti-spike antibody response to natural SARS-CoV-2 infection in the</li> </ul>
<ul> <li>Li, K., et al. Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19. Nature communications 11, 1-11 (2020).</li> <li>Wei, J., et al. Anti-spike antibody response to natural SARS-CoV-2 infection in the</li> </ul>
<ul> <li>526 infection and recovery from COVID-19. <i>Nature communications</i> 11, 1-11 (2020).</li> <li>527 16. Wei, J., et al. Anti-spike antibody response to natural SARS-CoV-2 infection in the</li> </ul>
527 16. Wei, J., et al. Anti-spike antibody response to natural SARS-CoV-2 infection in the
528 general population. <i>Nature communications</i> <b>12</b> , 1-12 (2021).
529 17. Sethuraman, N., Jeremiah, S.S. & Ryo, A. Interpreting diagnostic tests for SARS-
530 CoV-2. <i>Jama</i> <b>323</b> , 2249-2251 (2020).
531 18. Zheng, S., et al. Viral load dynamics and disease severity in patients infected with
532 SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort
533 study. <i>bmj</i> <b>369</b> (2020).
534 19. Wölfel, R., et al. Virological assessment of hospitalized patients with COVID-2019.
535 <i>Nature</i> <b>581</b> , 465-469 (2020).
536 20. Guo, L., et al. Profiling early humoral response to diagnose novel coronavirus
537 disease (COVID-19). <i>Clinical infectious diseases</i> <b>71</b> , 778-785 (2020).
538 21. Xiang, F., et al. Antibody detection and dynamic characteristics in patients with
539 coronavirus disease 2019. <i>Clinical Infectious Diseases</i> <b>71</b> , 1930-1934 (2020).
540 22. To, K.KW., et al. Temporal profiles of viral load in posterior oropharyngeal saliva
samples and serum antibody responses during infection by SARS-CoV-2: an
542 observational cohort study. <i>The Lancet infectious diseases</i> <b>20</b> , 565-574 (2020).

543	23.	Seow, J., et al. Longitudinal observation and decline of neutralizing antibody
544	25.	responses in the three months following SARS-CoV-2 infection in humans. <i>Nature</i>
545		microbiology <b>5</b> , 1598-1607 (2020).
546	24.	Ibarrondo, F.J., et al. Rapid decay of anti–SARS-CoV-2 antibodies in persons with
547		mild Covid-19. New England Journal of Medicine <b>383</b> , 1085-1087 (2020).
548	25.	Long, QX., et al. Antibody responses to SARS-CoV-2 in patients with COVID-19.
549		Nature medicine <b>26</b> , 845-848 (2020).
550	26.	Jering, K.S., <i>et al.</i> Clinical characteristics and outcomes of hospitalized women
551		giving birth with and without COVID-19. JAMA internal medicine <b>181</b> , 714-717
552		(2021).
553	27.	Mullins, E., et al. Pregnancy and neonatal outcomes of COVID-19: coreporting of
554		common outcomes from PAN-COVID and AAP-SONPM registries. Ultrasound in
555		<i>Obstetrics &amp; Gynecology</i> <b>57</b> , 573-581 (2021).
556	28.	Smithgall, M.C., et al. Placental pathology in women vaccinated and unvaccinated
557		against SARS-CoV-2. American Journal of Obstetrics & Gynecology (2022).
558	29.	Yang, Y.J., et al. Association of gestational age at coronavirus disease 2019 (COVID-
559		19) vaccination, history of severe acute respiratory syndrome coronavirus 2 (SARS-
560		CoV-2) infection, and a vaccine booster dose with maternal and umbilical cord
561		antibody levels at delivery. Obstetrics & Gynecology 139, 373-380 (2022).
562	30.	Prabhu, M., et al. Antibody response to coronavirus disease 2019 (COVID-19)
563		messenger RNA vaccination in pregnant women and transplacental passage into
564		cord blood. Obstetrics and Gynecology <b>138</b> , 278 (2021).
565	31.	Shimabukuro, T.T., et al. Preliminary findings of mRNA Covid-19 vaccine safety in
566		pregnant persons. New England Journal of Medicine (2021).
567	32.	Vousden, N., et al. Severity of maternal infection and perinatal outcomes during
568		periods in which Wildtype, Alpha and Delta SARS-CoV-2 variants were dominant:
569		Data from the UK Obstetric Surveillance System national cohort. BMJ Medicine
570		<b>1</b> (2022).
571	33.	CDC Data Tracker.
572	34.	Havers, F.P., et al. Seroprevalence of antibodies to SARS-CoV-2 in 10 sites in the
573		United States, March 23-May 12, 2020. JAMA internal medicine 180, 1576-1586
574		(2020).
575	35.	Stan Development Team. RStan: The R interface to Stan. 2020; Available from:
576		https://mc-stan.org/.
577		
578		
579		
2,2		

# 580 Supplementary information

### 581

	Mean/Count
	-
	n = 2618
ETHNICITY	
NOT HISPANIC OR LATINO OR SPANISH ORIGIN	1724 (65.9%)
HISPANIC OR LATINO OR SPANISH ORIGIN	216 (8.3%)
AFRICAN AMERICAN	1 (0%)
MULTI-RACIAL	1 (0%)
UNKNOWN	676 (25.8%)
RACE	
WHITE	1315 (50.2%)
ASIAN	325 (12.4%)
BLACK OR AFRICAN AMERICAN	166 (6.3%)
AMERICAN INDIAN OR ALASKA NATION	6 (0.2%)
NAT.HAWAIIAN/OTH.PACIFIC ISLAND	3 (0.1%)
ASHKENAZI JEWISH	2 (0.1%)
MULTIPLE RACES REPORTED	14 (0.5%)
OTHER COMBINATIONS NOT DESCRIBED	253 (9.7%)
UNKNOWN	80 (3.1%)
Mom Age (SD) years	34.4 (5.0)
Gestational Age at delivery (SD) weeks	38.8 (2.1)

582 Table S1: Patient demographics

Parameter	Symbol	Definition	Prior	Units	Range
category					
Pregnant	$\lambda_{ au}$	force of infection of pregnant	uniform (0,1)	week <sup>-1</sup>	[0,1]
patients		patients; 1 / (average time to			
		challenge by the virus for			
		pregnant patients)			
	τ	1 / (average time lag between	gamma (4,3)	week <sup>-1</sup>	[0,5]

		1		1	· · · · · · · · · · · · · · · · · · ·
		virus detection and antibody			
		detection)			
	σ	1 / (average time lag between	uniform (0,1)	week <sup>-1</sup>	[0,1]
		middle infection and past			
		infection)			
	β	antibody decaying rate in	uniform (0,1)	na	[0,1]
		pregnant patients			
	$y_{00}$	proportion of people who are	beta (8,2)	na	[0,1]
		never exposed yet by April			
		20 <sup>th</sup> , 2020			
	<i>k</i> <sub>01</sub>	tool parameter in the initial	uniform (0,1)	na	[0,1]
		condition reparameterization			
	<i>k</i> <sub>11</sub>	tool parameter in the initial	uniform (0,1)	na	[0,1]
		condition reparameterization			
	<i>k</i> <sub>10</sub>	tool parameter in the initial	uniform (0,1)	na	[0,1]
		condition reparameterization			
General	α	infection fatality ratio for	uniform (0,1)	na	[0,1]
population		general population			
	ω	antibody decaying rate in	uniform (0,1)	na	[0,1]
		general population based on			
		ELISA test <sup>34</sup> .			

Table S2. A list of parameters, definitions and priors used in the Bayesian inference in the model of pregnant patients
and general population.

587

Parameter(unit)	Definition	Median	2.5%	97.5%
α (-)	Infection fatality ratio among general	0.0077	0.0067	0.0087
	population			
$\omega^{-1}$ (days)	1/antibody decaying rate among	209	152	333
	general population			

588 Table S3. Posterior estimates of parameters in general population.

Parameter	Model	n <sub>eff</sub>	Ŕ	Parameter	Model	n <sub>eff</sub>	Ŕ
τ	1	9902	1	- k <sub>10</sub>	1	9954	1
	2	7876	1		2	8854	1
	3	9516	1		3	11699	1
	4	8251	1		4	8544	1
	1	10448	1		1	13671	1
σ	2	8744	1	17	2	13344	1
σ	3	11928	1	<i>k</i> <sub>11</sub>	3	13863	1
	4	8241	1 1		4	10818	1
	1	9982	1	$\lambda_{11}$	1	10128	1
β	2	8005	1	λ <sub>21</sub> 2	9273	1	
β	3	9154	1	$\lambda_{22}$		8502	1
	4	7953	1	$\lambda_{31}$		10948	1
	1	9330	1	$\lambda_{32}$	3	9698	1
27	2	10350	1	$\lambda_{33}$		9549	1
$\mathcal{Y}_{00}$	3	8152	1	$\lambda_{41}$		12655	1
	4	5675	1	$\lambda_{42}$		7391	1
1-	1	19436	1	$\lambda_{43}$	4	7333	1
	2	19826	1	$\lambda_{44}$	4		
k <sub>01</sub>	3	19595	1			7116	1
	4	17016	1				


**590** Table S4. The effective sample size  $(n_{eff})$  and the Gelman-Rubin $(\hat{R})$  diagnostic for the four models.

Model	Estimation of effectiveness of shielding (95% CrI)
Model 1	53.4% (23.5%, 72.1%)
Model 2	52.0% (16.4%, 71.1%)
Model 3	48.4% (11.4%, 67.8%)
Model 4	47.3% (6.1%, 67.5%)

**<sup>592</sup>** Table S5. Estimation of effectiveness of shielding from the four models.

593

Supplementary Figure 1



594


Figure S1. Time course of the SARS-CoV-2 infection among general from January 1<sup>st</sup>, 2020 to December
31st, 2020. The orange solid circles and black error bars represent the measured seroprevalence and their
credible intervals respectively. The blue and orange lines show the median of predictions of seroprevalence
and exposure among general population in New York City, while the shaded areas correspond to the 95%
credible intervals.

600

We conducted a sensitivity analysis around the choice of prior of the initial conditional of proportion of pregnant patients who were not exposed previously by 20 April 2020 (numerically equals to 1 minus the level of exposure in pregnant patients by 20 April 2020). The results showed that the median and 50% credible band of posterior estimates are very robust (Figure S2) although a heavy left tail in the 90% and 95% credible band (Figure S3) are estimated when the priors are very weak, for example uniform (0,1). However, considering the transmission speed and antibody decaying rate

- it is reasonable to choose a relative formative prior, such as beta (2,1) and beta (8,2)
- and then the posterior estimates are more concentrated around 0.85.

#### 610




611

612 Figure S2. Comparisons of posteriors with different significant levels (50%, 90% and 95%) for the proportion of pregnant

613 patients who were not exposed previously by 20 April 2020 (numerically equals to 1 minus the level of exposure in


614 pregnant patients by 20 April 2020).



615

616 Figure S3. Comparisons of priors and posteriors for the proportion of pregnant patients who were not exposed previously

617 by 20 April 2020 (numerically equals to 1 minus the level of exposure in pregnant patients by 20 April 2020).





621